Integra Lifesciences Corporation

Integra Lifesciences Corporation, operating as Jarit, a subsidiary of Integra Lifesciences Holdings, supplies specialized surgical instruments, neurosurgical equipment, tissue ablation systems, and maintenance services to federal healthcare agencies as a prime contractor on full-and-open purchase orders and delivery orders, with no set-aside posture across its federal footprint.

Integra Lifesciences Corporation maintains its headquarters in Princeton, New Jersey and operates as a for-profit corporate entity. The company competes without small-business set-asides across all recent awards—a full-and-open posture reflecting its scale and position as an original equipment manufacturer across multiple surgical and medical device categories. Primary NAICS concentration sits in Surgical Appliance and Supplies Manufacturing (1,792 awards) and Surgical and Medical Instrument Manufacturing (1,239 awards), with PSC coding dominated by Medical and Surgical Instruments, Equipment, and Supplies (4,919 awards). The company's federal footprint spans 5,403 total awards since 2001, with combined potential value of $73.2 million and $47.7 million obligated to date (65% execution rate). Activity has held flat in recent years—16 to 17 awards per year across 2022–2026—after a longer growth arc from 2001 onward.

Customer concentration centers on Department of Veterans Affairs VISNs and military healthcare. The top five customers account for 29% of awards by count and 38% of combined potential value by dollars: Department of the Army Medical Command (315 awards, $12.1 million), Department of the Navy Bureau of Medicine and Surgery (455 awards, $7.3 million), Department of Veterans Affairs VISN 22 (288 awards, $3.6 million), Department of Veterans Affairs VISN 17 (223 awards, $2.7 million), and Department of Veterans Affairs VISN 6 (229 awards, $2.6 million). Army Medical Command anchors the largest dollar concentration despite lower award count, reflecting higher average contract value from that customer. Navy BUMED leads in award frequency, placing 455 orders across the portfolio—predominantly delivery orders under a single-award IDIQ valued at $346,857.80 for Integra Probe Kit 2 Plus brain probe kits compatible with Licox oxygen monitors, running through May 9, 2028. The VA network spread is fragmented across VISNs 1 through 23, with routine purchase orders for surgical implants, TRUDI and Acclarent neurosurgical navigation system maintenance, CUSA ultrasonic tissue ablation systems, surgical shavers, and headlight systems.

Integra Lifesciences holds a single-award IDIQ with Navy BUMED (Indefinite Delivery Contract W81K0008A0031, 32 task orders, $1.2 million combined potential value) and seats on several BPAs including Indian Health Service and Department of Health and Human Services vehicles. Representative recent work includes a $432,444 sole-source ultrasonic tissue ablation system from VA VISN 6 (September 2024), a $369,073 sole-source Integra Ultrasonic Surgical Aspirator System for VA VISN 6 (May 2025), a $150,000 TRU DI ENT Navigation System service agreement from VA VISN 21 (August 2025), a $131,040 five-year maintenance agreement on cavitational ultrasonic surgical aspiration systems from Defense Health Agency (September 2025), and delivery orders for brain probe kits from Navy BUMED in the $40,000 to $44,000 range (2024–2025). Recent VA purchase orders span multiple VISNs and cover skull clamps, prosthetic implants, ENT surgical shavers, TRUDI navigation system maintenance (VISN 4, VISN 8, VISN 10, VISN 23), maintenance agreements, and tissue ablation systems. NIH Clinical Center has awarded equipment and cordless headlight orders, with the most recent a $88,210 cordless headlight system and batteries (July 2025). All primary awards carry firm fixed price and no set-aside designation, consistent with OEM status and original-equipment-manufacturer (OEM) authorization from device partners such as Acclarent.

Integra Lifesciences maintains a subcontract footprint routed through Cardinal Health 200, LLC, a medical device distributor. Sixteen sub-awards between 2022 and 2025 involve the delivery of surgical supplies, dressings, hemostats, stints, and other consumables through Cardinal Health's federal supply channels. The sub work is ancillary to the company's primary prime contracting relationship and does not materially reshape the prime-dominant character of the portfolio. Recompete exposure in the next twenty-four months is minimal—four awards with combined potential value of $322 thousand completing by October 2027—reflecting the prevalence of long-term maintenance service agreements and IDIQs already in place.